136 related articles for article (PubMed ID: 12131427)
21. Effects of fibronectin on osteoinductive capability of fresh iliac bone marrow aspirate in posterolateral spinal fusion in rabbits.
Koga A; Tokuhashi Y; Ohkawa A; Nishimura T; Takayama K; Ryu J
Spine (Phila Pa 1976); 2008 May; 33(12):1318-23. PubMed ID: 18496343
[TBL] [Abstract][Full Text] [Related]
22. Strut allograft union and remodeling using rhBMP-2 in a spinal corpectomy model.
White KK; Bawa M; Ahn JS; Farnsworth CL; Faro FD; Mahar AT; Wedemeyer M; Garfin SR; Newton PO
Spine (Phila Pa 1976); 2005 Jun; 30(12):1386-95. PubMed ID: 15959367
[TBL] [Abstract][Full Text] [Related]
23. Recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge with an osteoconductive bulking agent in posterolateral arthrodesis with instrumentation. A prospective randomized trial.
Dawson E; Bae HW; Burkus JK; Stambough JL; Glassman SD
J Bone Joint Surg Am; 2009 Jul; 91(7):1604-13. PubMed ID: 19571082
[TBL] [Abstract][Full Text] [Related]
24. Recombinant human bone morphogenetic protein-2 overcomes the inhibitory effect of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), on posterolateral lumbar intertransverse process spine fusion.
Martin GJ; Boden SD; Titus L
Spine (Phila Pa 1976); 1999 Nov; 24(21):2188-93; discussion 2193-4. PubMed ID: 10562982
[TBL] [Abstract][Full Text] [Related]
25. Is lumbar facet fusion biomechanically equivalent to lumbar posterolateral onlay fusion?
Toth JM; Foley KT; Wang M; Seim HB; Simon Turner A
J Neurosurg Spine; 2017 May; 26(5):586-593. PubMed ID: 28156207
[TBL] [Abstract][Full Text] [Related]
26. 2000 Young Investigator Research Award winner. Evaluation of OP-1 as a graft substitute for intertransverse process lumbar fusion.
Grauer JN; Patel TC; Erulkar JS; Troiano NW; Panjabi MM; Friedlaender GE
Spine (Phila Pa 1976); 2001 Jan; 26(2):127-33. PubMed ID: 11154530
[TBL] [Abstract][Full Text] [Related]
27. Repeat use of human recombinant bone morphogenetic protein-2 for second level lumbar arthrodesis.
Singh K; Dumonski M; Stanley T; Ponnappan R; Phillips FM
Spine (Phila Pa 1976); 2011 Feb; 36(3):192-6. PubMed ID: 20634780
[TBL] [Abstract][Full Text] [Related]
28. Initial fusion rates with recombinant human bone morphogenetic protein-2/compression resistant matrix and a hydroxyapatite and tricalcium phosphate/collagen carrier in posterolateral spinal fusion.
Glassman SD; Dimar JR; Carreon LY; Campbell MJ; Puno RM; Johnson JR
Spine (Phila Pa 1976); 2005 Aug; 30(15):1694-8. PubMed ID: 16094268
[TBL] [Abstract][Full Text] [Related]
29. Experimental spinal fusion with use of recombinant human bone morphogenetic protein 2.
Itoh H; Ebara S; Kamimura M; Tateiwa Y; Kinoshita T; Yuzawa Y; Takaoka K
Spine (Phila Pa 1976); 1999 Jul; 24(14):1402-5. PubMed ID: 10423783
[TBL] [Abstract][Full Text] [Related]
30. Experimental spinal fusion with recombinant human bone morphogenetic protein-2.
Schimandle JH; Boden SD; Hutton WC
Spine (Phila Pa 1976); 1995 Jun; 20(12):1326-37. PubMed ID: 7676329
[TBL] [Abstract][Full Text] [Related]
31. Comparative study of fusion rate induced by different dosages of Escherichia coli-derived recombinant human bone morphogenetic protein-2 using hydroxyapatite carrier.
Lee JH; Yu CH; Yang JJ; Baek HR; Lee KM; Koo TY; Chang BS; Lee CK
Spine J; 2012 Mar; 12(3):239-48. PubMed ID: 22341396
[TBL] [Abstract][Full Text] [Related]
32. The use of cultured bone marrow cells in type I collagen gel and porous hydroxyapatite for posterolateral lumbar spine fusion.
Minamide A; Yoshida M; Kawakami M; Yamasaki S; Kojima H; Hashizume H; Boden SD
Spine (Phila Pa 1976); 2005 May; 30(10):1134-8. PubMed ID: 15897826
[TBL] [Abstract][Full Text] [Related]
33. The effect of osteogenic protein-1 in instrumented and noninstrumented posterolateral fusion in rabbits.
Jenis LG; Wheeler D; Parazin SJ; Connolly RJ
Spine J; 2002; 2(3):173-8. PubMed ID: 14589490
[TBL] [Abstract][Full Text] [Related]
34. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages.
Haid RW; Branch CL; Alexander JT; Burkus JK
Spine J; 2004; 4(5):527-38; discussion 538-9. PubMed ID: 15363423
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in posterolateral lumbar fusion: an open, active-controlled, randomized, multicenter trial.
Cho JH; Lee JH; Yeom JS; Chang BS; Yang JJ; Koo KH; Hwang CJ; Lee KB; Kim HJ; Lee CK; Kim H; Suk KS; Nam WD; Han J
Spine J; 2017 Dec; 17(12):1866-1874. PubMed ID: 28652196
[TBL] [Abstract][Full Text] [Related]
36. The effects of BMP-7 in a rat posterolateral intertransverse process fusion model.
Salamon ML; Althausen PL; Gupta MC; Laubach J
J Spinal Disord Tech; 2003 Feb; 16(1):90-5. PubMed ID: 12571490
[TBL] [Abstract][Full Text] [Related]
37. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis.
Dimar JR; Glassman SD; Burkus JK; Pryor PW; Hardacker JW; Carreon LY
J Bone Joint Surg Am; 2009 Jun; 91(6):1377-86. PubMed ID: 19487515
[TBL] [Abstract][Full Text] [Related]
38. Effect of bone morphogenetic protein-2/hydroxyapatite on ankle fusion with bone defect in a rabbit model: a pilot study.
Dang LHN; Lee KB
J Orthop Surg Res; 2020 Aug; 15(1):366. PubMed ID: 32859231
[TBL] [Abstract][Full Text] [Related]
39. The Marshall R. Urist Young Investigator Award. Gene expression during autograft lumbar spine fusion and the effect of bone morphogenetic protein 2.
Morone MA; Boden SD; Hair G; Martin GJ; Racine M; Titus L; Hutton WC
Clin Orthop Relat Res; 1998 Jun; (351):252-65. PubMed ID: 9646769
[TBL] [Abstract][Full Text] [Related]
40. Lower dose of rhBMP-2 achieves spine fusion when combined with an osteoconductive bulking agent in non-human primates.
Barnes B; Boden SD; Louis-Ugbo J; Tomak PR; Park JS; Park MS; Minamide A
Spine (Phila Pa 1976); 2005 May; 30(10):1127-33. PubMed ID: 15897825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
